Cargando…

Molecular insights into the improved clinical performance of PEGylated interferon therapeutics: a molecular dynamics perspective

PEGylation is a widely adopted process to covalently attach a polyethylene glycol (PEG) polymer to a protein drug for the purpose of optimizing drug clinical performance. While the outcomes of PEGylation in imparting pharmacological advantages have been examined through experimental studies, the und...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Dong, Smolin, Nikolai, Shaw, Rance K., Battey, Samuel R., Tao, Aoxiang, Huang, Yuying, Rahman, Shaikh Emdadur, Caylor, Matthew L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society of Chemistry 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9077387/
https://www.ncbi.nlm.nih.gov/pubmed/35541455
http://dx.doi.org/10.1039/c7ra12480e
_version_ 1784702108733276160
author Xu, Dong
Smolin, Nikolai
Shaw, Rance K.
Battey, Samuel R.
Tao, Aoxiang
Huang, Yuying
Rahman, Shaikh Emdadur
Caylor, Matthew L.
author_facet Xu, Dong
Smolin, Nikolai
Shaw, Rance K.
Battey, Samuel R.
Tao, Aoxiang
Huang, Yuying
Rahman, Shaikh Emdadur
Caylor, Matthew L.
author_sort Xu, Dong
collection PubMed
description PEGylation is a widely adopted process to covalently attach a polyethylene glycol (PEG) polymer to a protein drug for the purpose of optimizing drug clinical performance. While the outcomes of PEGylation in imparting pharmacological advantages have been examined through experimental studies, the underlying molecular mechanisms remain poorly understood. Using interferon (IFN) as a representative model system, we carried out comparative molecular dynamics (MD) simulations of free PEGx, apo-IFN, and PEGx-IFN (x = 50, 100, 200, 300) to characterize the molecular-level changes in IFN introduced by PEGylation. The simulations yielded molecular evidence directly linked to the improved protein stability, bioavailability, retention time, as well as the decrease in protein bioactivity with PEG conjugates. Our results indicate that there is a tradeoff between the benefits and costs of PEGylation. The optimal PEG chain length used in PEGylation needs to strike a good balance among the competing factors and maximizes the overall therapeutic efficacy of the protein drug. We anticipate the study will have a broad implication for protein drug design and development, and provide a unique computational approach in the context of optimizing PEGylated protein drug conjugates.
format Online
Article
Text
id pubmed-9077387
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher The Royal Society of Chemistry
record_format MEDLINE/PubMed
spelling pubmed-90773872022-05-09 Molecular insights into the improved clinical performance of PEGylated interferon therapeutics: a molecular dynamics perspective Xu, Dong Smolin, Nikolai Shaw, Rance K. Battey, Samuel R. Tao, Aoxiang Huang, Yuying Rahman, Shaikh Emdadur Caylor, Matthew L. RSC Adv Chemistry PEGylation is a widely adopted process to covalently attach a polyethylene glycol (PEG) polymer to a protein drug for the purpose of optimizing drug clinical performance. While the outcomes of PEGylation in imparting pharmacological advantages have been examined through experimental studies, the underlying molecular mechanisms remain poorly understood. Using interferon (IFN) as a representative model system, we carried out comparative molecular dynamics (MD) simulations of free PEGx, apo-IFN, and PEGx-IFN (x = 50, 100, 200, 300) to characterize the molecular-level changes in IFN introduced by PEGylation. The simulations yielded molecular evidence directly linked to the improved protein stability, bioavailability, retention time, as well as the decrease in protein bioactivity with PEG conjugates. Our results indicate that there is a tradeoff between the benefits and costs of PEGylation. The optimal PEG chain length used in PEGylation needs to strike a good balance among the competing factors and maximizes the overall therapeutic efficacy of the protein drug. We anticipate the study will have a broad implication for protein drug design and development, and provide a unique computational approach in the context of optimizing PEGylated protein drug conjugates. The Royal Society of Chemistry 2018-01-09 /pmc/articles/PMC9077387/ /pubmed/35541455 http://dx.doi.org/10.1039/c7ra12480e Text en This journal is © The Royal Society of Chemistry https://creativecommons.org/licenses/by/3.0/
spellingShingle Chemistry
Xu, Dong
Smolin, Nikolai
Shaw, Rance K.
Battey, Samuel R.
Tao, Aoxiang
Huang, Yuying
Rahman, Shaikh Emdadur
Caylor, Matthew L.
Molecular insights into the improved clinical performance of PEGylated interferon therapeutics: a molecular dynamics perspective
title Molecular insights into the improved clinical performance of PEGylated interferon therapeutics: a molecular dynamics perspective
title_full Molecular insights into the improved clinical performance of PEGylated interferon therapeutics: a molecular dynamics perspective
title_fullStr Molecular insights into the improved clinical performance of PEGylated interferon therapeutics: a molecular dynamics perspective
title_full_unstemmed Molecular insights into the improved clinical performance of PEGylated interferon therapeutics: a molecular dynamics perspective
title_short Molecular insights into the improved clinical performance of PEGylated interferon therapeutics: a molecular dynamics perspective
title_sort molecular insights into the improved clinical performance of pegylated interferon therapeutics: a molecular dynamics perspective
topic Chemistry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9077387/
https://www.ncbi.nlm.nih.gov/pubmed/35541455
http://dx.doi.org/10.1039/c7ra12480e
work_keys_str_mv AT xudong molecularinsightsintotheimprovedclinicalperformanceofpegylatedinterferontherapeuticsamoleculardynamicsperspective
AT smolinnikolai molecularinsightsintotheimprovedclinicalperformanceofpegylatedinterferontherapeuticsamoleculardynamicsperspective
AT shawrancek molecularinsightsintotheimprovedclinicalperformanceofpegylatedinterferontherapeuticsamoleculardynamicsperspective
AT batteysamuelr molecularinsightsintotheimprovedclinicalperformanceofpegylatedinterferontherapeuticsamoleculardynamicsperspective
AT taoaoxiang molecularinsightsintotheimprovedclinicalperformanceofpegylatedinterferontherapeuticsamoleculardynamicsperspective
AT huangyuying molecularinsightsintotheimprovedclinicalperformanceofpegylatedinterferontherapeuticsamoleculardynamicsperspective
AT rahmanshaikhemdadur molecularinsightsintotheimprovedclinicalperformanceofpegylatedinterferontherapeuticsamoleculardynamicsperspective
AT caylormatthewl molecularinsightsintotheimprovedclinicalperformanceofpegylatedinterferontherapeuticsamoleculardynamicsperspective